Cerebral Palsy (Spastic Diplegia)
2157
relevant articles (139 outcomes,
346 trials/studies)
found for this Disease
Description:
A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
Also Known As:
Spastic Diplegia; Cerebral Palsy, Congenital; Cerebral Palsy, Spastic; Athetoid Cerebral Palsy; Dyskinetic Cerebral Palsy; CP (Cerebral Palsy); Cerebral Palsy, Athetoid; Cerebral Palsy, Atonic; Cerebral Palsy, Diplegic, Infantile; Cerebral Palsy, Dyskinetic; Cerebral Palsy, Dystonic-Rigid; Cerebral Palsy, Hypotonic; Cerebral Palsy, Mixed; Cerebral Palsy, Monoplegic, Infantile; Cerebral Palsy, Quadriplegic, Infantile; Cerebral Palsy, Rolandic Type; Congenital Cerebral Palsy; Diplegia, Spastic; Infantile Cerebral Palsy, Diplegic; Infantile Cerebral Palsy, Monoplegic; Infantile Cerebral Palsy, Quadriplegic; Little's Disease; Monoplegic Infantile Cerebral Palsy; Rolandic Type Cerebral Palsy; Atonic Cerebral Palsy; Cerebral Palsies, Athetoid; Cerebral Palsies, Dyskinetic; Cerebral Palsies, Dystonic-Rigid; Cerebral Palsies, Monoplegic; Cerebral Palsy, Dystonic Rigid; Cerebral Palsy, Monoplegic; Diplegias, Spastic; Dystonic-Rigid Cerebral Palsies; Dystonic-Rigid Cerebral Palsy; Hypotonic Cerebral Palsies; Hypotonic Cerebral Palsy; Mixed Cerebral Palsies; Mixed Cerebral Palsy; Monoplegic Cerebral Palsies; Spastic Cerebral Palsies; Spastic Cerebral Palsy; Spastic Diplegias; Diplegic Infantile Cerebral Palsy; Little Disease; Monoplegic Cerebral Palsy; Quadriplegic Infantile Cerebral Palsy
Relationship Network
Disease Context: Research Results
Related Diseases
Experts
| 1. | Miller, Freeman:
18 articles
(10/2008 - 02/2002)
|
| 2. | Dabney, Kirk W:
8 articles
(10/2008 - 02/2002)
|
| 3. | Graham, H Kerr:
7 articles
(01/2008 - 12/2002)
|
| 4. | Graham, H K:
7 articles
(09/2003 - 01/2000)
|
| 5. | Park, Eun Sook:
6 articles
(08/2008 - 04/2004)
|
| 6. | Becher, Jules G:
6 articles
(06/2008 - 05/2005)
|
| 7. | Heinen, F:
6 articles
(04/2006 - 02/2000)
|
| 8. | Steinbok, Paul:
5 articles
(09/2007 - 03/2002)
|
| 9. | Berweck, Steffen:
5 articles
(11/2006 - 01/2004)
|
| 10. | Heinen, Florian:
5 articles
(11/2006 - 01/2004)
|
Drugs and Biologics
Drugs and Important Biological Agents (IBA) related to Cerebral Palsy:
| 1. | Botulinum Toxins (Botulinum Toxin)IBA
|
| 2. | Botulinum Toxin Type A (Botox)FDA Link
|
| 3. | BaclofenFDA LinkGeneric
|
| 4. | FlexorIBA
|
| 5. | Magnesium Sulfate (Sulfate, Magnesium)FDA LinkGeneric
06/01/2009
- " Antenatal magnesium sulfate was associated with a significant reduction in the risk of cerebral palsy (relative risk [RR], 0.69; 95% confidence interval [CI], 0.55-0.88), moderate or severe cerebral palsy (RR, 0.64; 95% CI, 0.44-0.92), and substantial gross motor dysfunction (RR, 0.60; 95% CI, 0.43-0.83). " 08/01/2009
- " When only neuroprotection trials (four trials, 4,324 fetuses/infants) are analyzed, in utero exposure to magnesium sulfate additionally reduced the primary outcome of death or cerebral palsy. " 06/01/2009
- " There were no significant effects of antenatal magnesium sulfate on combined rates of mortality with neurologic outcomes, except in the studies where the primary intent was neuroprotection, where there was a reduction in death or cerebral palsy (RR 0.85; 95% CI 0.74-0.98; four trials; 4,446 infants). " 06/01/2009
- " We conducted a systematic review and metaanalysis of randomized controlled trials to determine whether magnesium sulfate administered to women at risk of preterm delivery before 34 weeks of gestation may reduce the risk of cerebral palsy in their children. " 09/01/1996
- " CONCLUSIONS: A randomized trial of maternally administered intrapartum magnesium sulfate to reduce the rate of cerebral palsy in surviving preterm neonates would be a formidable undertaking, requiring a concerted multicentered effort."
Order ALL the reference details at left...
|
| 6. | pamidronate (APD)FDA LinkGeneric
|
| 7. | Nitrous Oxide (Laughing Gas)IBA
|
| 8. | OxygenIBA
|
| 9. | Diazepam (Valium)FDA LinkGeneric
|
| 10. | Adrenal Cortex Hormones (Corticosteroids)IBA
|
|
Therapies and Procedures